These models would enable the isolation of the mutant PAH, determination of its molecular weight, assessment of its catalytic activity, and potentially the resolution of its three-dimensional structure by crystallographic methods, ultimately aiming to elucidate the functional impact of this duplication in the clinical context of PKU and HPA. The gene discussed is PAH; the disease is phenylketonuria.